Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
48.62
+0.12 (0.25%)
Sep 4, 2026, 11:50 AM EDT - Market open
Rigel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 276.52 | 294.02 | 179.28 | 115.78 | 115.74 | 138.74 |
Other Revenue | 0.27 | 0.27 | - | 1.1 | - | - |
| 276.79 | 294.28 | 179.28 | 116.88 | 115.74 | 138.74 | |
Revenue Growth | 3.31% | 64.15% | 53.38% | 0.98% | -16.57% | 27.73% |
Cost of Revenue | 67.51 | 52.92 | 42.03 | 31.63 | 62.02 | 66.32 |
Gross Profit | 209.27 | 241.37 | 137.25 | 85.25 | 53.72 | 72.42 |
Selling, General & Admin | 122.22 | 115.9 | 113.06 | 105.74 | 112.45 | 91.89 |
Operating Expenses | 122.22 | 115.9 | 113.06 | 105.74 | 112.45 | 91.89 |
Operating Income | 87.05 | 125.47 | 24.19 | -20.49 | -58.73 | -19.48 |
Interest Expense | -5.81 | -7.32 | -7.92 | -6.87 | -3.71 | -4.86 |
Interest & Investment Income | 4.33 | 3.68 | 2.09 | 2.27 | 0.68 | 0.05 |
EBT Excluding Unusual Items | 85.58 | 121.83 | 18.37 | -25.09 | -61.75 | -24.29 |
Merger & Restructuring Charges | - | - | - | - | -1.32 | -3.52 |
Other Unusual Items | - | - | - | - | 4.5 | 10.5 |
Pretax Income | 85.58 | 121.83 | 18.37 | -25.09 | -58.57 | -17.31 |
Income Tax Expense | -236.33 | -245.2 | 0.88 | - | - | 0.61 |
Net Income | 321.91 | 367.02 | 17.49 | -25.09 | -58.57 | -17.91 |
Net Income to Common | 321.91 | 367.02 | 17.49 | -25.09 | -58.57 | -17.91 |
Net Income Growth | 229.08% | 1999.08% | - | - | - | - |
Shares Outstanding (Basic) | 18 | 18 | 18 | 17 | 17 | 17 |
Shares Outstanding (Diluted) | 20 | 19 | 18 | 17 | 17 | 17 |
Shares Change | 8.67% | 6.52% | 1.64% | 2.07% | -0.00% | 1.03% |
EPS (Basic) | 17.59 | 20.40 | 0.99 | -1.44 | -3.44 | -1.05 |
EPS (Diluted) | 16.45 | 19.48 | 0.99 | -1.44 | -3.44 | -1.05 |
EPS Growth | 202.71% | 1867.68% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 79.39 | 75.66 | 31.44 | -5.74 | -74.21 | 5.25 |
Free Cash Flow Per Share | 4.06 | 4.02 | 1.78 | -0.33 | -4.35 | 0.31 |
Gross Margin | 75.61% | 82.02% | 76.56% | 72.94% | 46.41% | 52.20% |
Operating Margin | 31.45% | 42.63% | 13.49% | -17.53% | -50.74% | -14.04% |
Profit Margin | 116.30% | 124.72% | 9.75% | -21.47% | -50.61% | -12.91% |
Free Cash Flow Margin | 28.68% | 25.71% | 17.53% | -4.91% | -64.11% | 3.79% |
EBITDA | 89.7 | 127.88 | 26.42 | -19.25 | -57.73 | -18.31 |
EBITDA Margin | 32.41% | 43.45% | 14.74% | -16.47% | -49.88% | -13.20% |
D&A For EBITDA | 2.65 | 2.42 | 2.23 | 1.24 | 1 | 1.16 |
EBIT | 87.05 | 125.47 | 24.19 | -20.49 | -58.73 | -19.48 |
EBIT Margin | 31.45% | 42.63% | 13.49% | -17.53% | -50.74% | -14.04% |
Effective Tax Rate | - | - | 4.80% | - | - | - |
Revenue as Reported | 276.79 | 294.28 | 179.28 | 116.88 | 120.24 | 149.24 |
Advertising Expenses | - | 2.3 | 2.1 | 3.1 | - | - |